Wikidata

(Q63317980)

English

Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod

clinical trial

In more languages

Statements

short name
TOFIINGO (English)
0 references
title
A 32-week, Patient- and Rater-blinded, Randomized, Multi-center, Parallel-group Study to Evaluate Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis Transferred From Previous Treatment With Natalizumab to Fingolimod (FTY720) (English)
0 references
medical condition
sclerosis
0 references
multiple sclerosis
0 references
sponsor
Novartis
0 references
country
Australia
0 references
Austria
0 references
Czech Republic
0 references
Finland
0 references
Germany
0 references
Greece
0 references
Hungary
0 references
Israel
0 references
Italy
0 references
Spain
0 references
Switzerland
0 references
main subject
tolerability
0 references
safety
0 references
start time
September 2011
0 references
end time
November 2012
0 references
number of participants
142
0 references
research site
Novartis
0 references
minimum age
18 year
0 references
maximum age
65 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q63317980&oldid=1857118932"